The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2
Curr Opin Pharmacol. 2023 Sep 19;73:102404. doi: 10.1016/j.coph.2023.102404. Online ahead of print.ABSTRACTInfectious agents such as human immune deficiency virus-1 (HIV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) use host proteins to infect, replicate, and induce inflammation within the host. A critical component of these diseases is the axis between pannexin-1 channels, extracellular ATP, and purinergic receptors. Here, we describe the potential therapeutic role of Pannexin-1/purinergic approaches to prevent or reduce the devastating consequences of these pathogens.PMID:37734241 | DOI:10.1016/j.coph...
Source: Current Opinion in Pharmacology - September 21, 2023 Category: Drugs & Pharmacology Authors: Cristian A Hernandez Eliseo A Eugenin Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Oct;72:102395. doi: 10.1016/j.coph.2023.102395. Epub 2023 Aug 26.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Oct;72:102395. doi: 10.1016/j.coph.2023.102395. Epub 2023 Aug 26.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Oct;72:102395. doi: 10.1016/j.coph.2023.102395. Epub 2023 Aug 26.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Oct;72:102395. doi: 10.1016/j.coph.2023.102395. Epub 2023 Aug 26.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Oct;72:102395. doi: 10.1016/j.coph.2023.102395. Epub 2023 Aug 26.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Aug 26;72:102395. doi: 10.1016/j.coph.2023.102395. Online ahead of print.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we pr...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Aug 26;72:102395. doi: 10.1016/j.coph.2023.102395. Online ahead of print.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we pr...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
Pharmacologic treatment of gastroparesis: What is (still) on the horizon?
Curr Opin Pharmacol. 2023 Aug 26;72:102395. doi: 10.1016/j.coph.2023.102395. Online ahead of print.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we pr...
Source: Current Opinion in Pharmacology - August 28, 2023 Category: Drugs & Pharmacology Authors: D Schweckendiek D Pohl Source Type: research
